The expression of Rho proteins decreases with human brain tumor progression:: Potential tumor markers

被引:90
作者
Forget, MA
Desrosiers, RR
Del Maestro, RF
Moumdjian, R
Shedid, D
Berthelet, F
Béliveau, R
机构
[1] Univ Quebec, Hop St Justine, Mol Med Lab, Montreal, PQ H3C 3P8, Canada
[2] McGill Univ, Montreal Neurol Inst, Ctr Rech Tumeurs Cerebrales, Montreal, PQ, Canada
[3] Hop Notre Dame de Bon Secours, Serv Neurochirurg, Montreal, PQ H2L 4K8, Canada
[4] Hop Notre Dame de Bon Secours, Dept Pathol, Montreal, PQ H2L 4K8, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
brain tumor; caveolin; glioma; human; marker; metastase; Rho proteins;
D O I
10.1023/A:1013884426692
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Astrocytic tumors are the most common human brain tumors. Establishment of tumor grade is a key determinant both in the choice of a therapeutic approach and in the prognosis. The diagnosis of astrocytic tumors is currently determined following histopathological analysis. The identification of molecular markers would offer a complementary tool for characterizing tumors with respect to their clinical behavior. In this study we determined the expression levels of 3 small GTP binding proteins (RhoA, RhoB and Rac1), of their inhibitor RhoGDI and of caveolin-1 in 24 human astrocytic tumors of grades I to IV. Our results demonstrated that the expression of RhoA and RhoB decreased significantly in all brain tumors studied and was inversely related with tumor of grade II to IV malignancy. The amount of caveolin-1 immunodetected was not significantly different from normal brain samples while the Rac1 expression level was diminished in astrocytic tumors of grades III and IV. Our finding that RhoA and RhoB expression levels are correlated to tumor malignancy suggests that they may serve as novel and efficient diagnostic markers for astrocytic brain tumors of histological grade II to IV and complement currently applied histopathological analysis.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 41 条
[1]   Motility and invasion are differentially modulated by Rho family GTPases [J].
Banyard, J ;
Anand-Apte, B ;
Symons, M ;
Zetter, BR .
ONCOGENE, 2000, 19 (04) :580-591
[2]  
Bender FC, 2000, CANCER RES, V60, P5870
[3]   Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice [J].
Chen, Z ;
Sun, JZ ;
Pradines, A ;
Favre, G ;
Adnane, J ;
Sebti, SM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (24) :17974-17978
[4]   Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma [J].
Cleverley, SC ;
Costello, PS ;
Henning, SW ;
Cantrell, DA .
ONCOGENE, 2000, 19 (01) :13-20
[5]  
del Peso L, 1997, ONCOGENE, V15, P3047
[6]   Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors [J].
Demeule, M ;
Shedid, D ;
Beaulieu, É ;
Del Maestro, RF ;
Moghrabi, A ;
Ghosn, PB ;
Moumdjian, R ;
Berthelet, F ;
Beliveau, R .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (01) :62-66
[7]   Expression of variant CD44 epitopes in human astrocytic brain tumors [J].
Eibl, RH ;
Pietsch, T ;
Moll, J ;
SkrochAngel, P ;
Heider, KH ;
vonAmmon, K ;
Wiestler, OD ;
Ponta, H ;
Kleihues, P ;
Herrlich, P .
JOURNAL OF NEURO-ONCOLOGY, 1995, 26 (03) :165-170
[8]  
Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO
[9]  
2-B
[10]   Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade [J].
Galbiati, F ;
Volonté, D ;
Engelman, JA ;
Watanabe, G ;
Burk, R ;
Pestell, RG ;
Lisanti, MP .
EMBO JOURNAL, 1998, 17 (22) :6633-6648